VERACYTE INC

Veracyte’s Decipher® proves its value in Phase III STAMPEDE: higher scores predict better abiraterone response in high‑risk prostate cancer.

Veracyte (VCYT) climbs 3.19% as insider buys 1,864 shares; now trading at $45.95 with 52‑week high $60.91 – discover key insights.

Veracyte (VCYT) climbs 2.3% to $44.79, nearing its 52‑week high, as strong liquidity and a growing precision‑medicine pipeline boost investor confidence.

Veracyte (VCYT) shares rise 1.58% on 21 Oct 2026, trading at $44.79 with a 200‑day SMA of $42.60, reflecting recent upward momentum and solid biotech fundamentals.